Arcus Biosciences Company

Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology.
Arcus’s lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment.
Adenosine receptor antagonists and inhibitors of adenosine production are expected to be highly synergistic with other immuno-oncology mechanisms, as well as with chemotherapy. Because of the promise of the adenosine pathway, several adenosine receptor antagonists that were discovered years ago and initially developed for other indications have been repurposed for oncology. Using our expertise in medicinal chemistry and drug discovery, we have generated novel, small molecule dual antagonists of key adenosine receptors A2aR and A2bR.
Technology: Personalised Medicine
Industry: P4 Medicine
Headquarters: United Kingdom
Founded Date: 2015
Employees Number: 11-50
Funding Status: IPO
Investors Number: 17
Total Funding: $226.7M
Estimated Revenue: $1M to $10M
Last Funding Type: Series C

Visit Website
webmaster@arcusbio.com
Register and Claim Ownership